The risk of the weight loss drug being prescribed outside its pharmaceutical indication was considered too high, while for children, the price was deemed inflated ...
Research suggests weight loss jabs like Wegovy and Mounjaro could stop people dying from heart attacks by boosting blood flow ...
The $166 bln Wegovy maker has effectively shed all its share-price gains from a pioneering obesity drug. The key problem: failing to build a vast supply chain for a remedy that could treat 1 ...
New research suggests popular GLP-1 weight loss drugs like Ozempic, Wegovy, and Mounjaro may raise the risk of osteoporosis and gout. A large five-year study found slightly higher rates of bone ...
Weight loss drugs are more popular than ever, even in cycling, but do the health benefits some are seeing outweigh the risks ...
“GLP‑1s have effectively created a third pillar of pharmacy spend and most employers don't yet have a mature playbook to manage it,” Conway said, adding that over half of employers now cite GLP‑1s as ...
Eli Lilly released new data on its oral pill, orforglipron, Thursday, showing it's almost as good as Ozempic. The pill may be available this spring.
Orforglipron led to greater weight loss than semaglutide tablets and could offer more effective oral alternative to jabs ...
Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...
Novo Nordisk will cut prices of the diabetes and weight loss drugs Ozempic, Rybelsus and Wegovy to $675 effective Jan. 1, 2027.
Amid efforts on several fronts to improve the affordability of its GLP-1 medications for diabetes and obesity, Novo Nordisk is taking a new approach by aiming straight for semaglutide’s list price. | ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results